Abstract: A method that calculates a setpoint for managing the fuel and electricity consumption of a hybrid motor vehicle includes: a) acquiring, by a navigation system on board the hybrid motor vehicle, a route to be traveled; b) dividing the route into consecutive portions; c) assigning attributes that characterize each portion; d) determining, for each of the portions, a curve or a map that links each fuel consumption value of the hybrid motor vehicle over the portion to a charge or discharge value of the traction battery; e) determining an optimal point of each curve or map, which makes it possible to minimize the fuel consumption of the hybrid motor vehicle over the entire route and to completely discharge the traction battery by the end of the route; and f) producing an energy management setpoint in accordance with the coordinates of the optimal points.

Abstract: A method for preserving the state of health of a traction battery of a hybrid motor vehicle includes: a) acquiring a journey to be made via a navigation system installed in the hybrid motor vehicle, b) dividing the journey into successive portions, c) allocating attributes characterising each of the portions, d) determining, for each of the portions, a curve or a map linking every fuel consumption value of the hybrid motor vehicle for the portion to a charge or discharge value of the traction battery, e) determining an optimal point on each curve or map that makes it possible to minimise the ageing of the traction battery over the entire journey and to ensure that the traction battery is completely discharged on completion of the journey, and f) generating an energy management setpoint depending on the coordinates of the optimal points.

Abstract: A method that calculates a setpoint for managing the fuel and electricity consumption of a hybrid motor vehicle includes: a) acquiring, by a navigation system on board the hybrid motor vehicle, a route to be traveled; b) dividing the route into consecutive portions; c) assigning attributes that characterize each portion; d) determining, for each of the portions, a curve or a map that links each fuel consumption value of the hybrid motor vehicle over the portion to a charge or discharge value of the traction battery; e) determining an optimal point of each curve or map, which makes it possible to minimize the fuel consumption of the hybrid motor vehicle over the entire route and to completely discharge the traction battery by the end of the route; and f) producing an energy management setpoint in accordance with the coordinates of the optimal points.

Abstract: The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium chloride, phenoxyethanol and phenylethyl alcohol.

Abstract: A first method for estimating a torque/force exerted by a load against an actuator driven by an electric motor against the load includes measuring motor current of the electric motor and measuring a position/angle or speed/angular speed of the actuator and includes calculating the torque/force exerted by the load against the actuator using at least a difference between a calculated motor torque/force and a calculated actuator-experienced torque/force. A second method includes measuring input voltage of the electric motor instead of measuring motor current. A third method includes measuring both motor current and input voltage. In one example, without limitation, the actuator is an automotive electromechanical brake caliper.

Abstract: A first method for estimating a torque/force exerted by a load against an actuator driven by an electric motor against the load includes measuring motor current of the electric motor and measuring a position/angle or speed/angular speed of the actuator and includes calculating the torque/force exerted by the load against the actuator using at least a difference between a calculated motor torque/force and a calculated actuator-experienced torque/force. A second method includes measuring input voltage of the electric motor instead of measuring motor current. A third method includes measuring both motor current and input voltage. In one example, without limitation, the actuator is an automotive electromechanical brake caliper.

Abstract: The present invention is directed to the use of benzethonium chloride, alone or in combination with phenoxyethanol or phenyl ethyl alcohol, to provide anti-microbial activity in pharmaceutical compositions. The present invention also provides methods of using benzethonium chloride, alone or in combination with phenoxyethanol or phenyl ethyl alcohol, to inhibit microbial growth in pharmaceutical compositions.

Abstract: The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium chloride, phenoxyethanol and phenylethyl alcohol.

Abstract: The present invention provides aqueous oral formulations containing sertraline, or a pharmaceutically acceptable salt thereof, and a sulfoalkyl ether cyclodextrin. The liquid formulations are pleasant tasting, convenient to use, and chemically and physically stable. The liquid formulations can be administered directly or diluted before administration. Unlike the commercially available ZOLOFT™ formulation, the liquid formulations herein do not precipitate upon dilution with water, fruit juices, sodas or other pharmaceutically acceptable oral liquid carriers. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over the marketed non-aqueous formulation and other cyclodextrin-containing formulations of sertraline. The formulation can be self-preserved against microbial growth. The SAE-CD-containing formulation of sertraline can be provided in liquid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid formulations can be prepared.

Abstract: The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parenteral administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared.

Abstract: The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parenteral administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared.